Drug intelligence / Profile preview

tebipenem pivoxil hydrobromide + aluminum hydroxide + magnesium hydroxide + simethicone

Development stage
Unknown
Lead developer
Spero Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is an **oral fixed-dose combination** of four components: - **Tebipenem pivoxil hydrobromide**: a prodrug of the carbapenem antibiotic tebipenem, designed for oral administration. It inhibits bacterial cell wall synthesis, making it active against a wide range of Gram-positive and Gram-negative bacteria, and is under development for indications such as complicated urinary tract infections (cUTI), pyelonephritis, and various respiratory and ear infections. The hydrobromide salt improves drug stability and formulation. - **Aluminum hydroxide** and **magnesium hydroxide**: antacids that neutralize gastric acid, providing relief of heartburn, indigestion, and acid-related symptoms. - **Simethicone**: an anti-foaming agent that reduces the surface tension of gas bubbles in the GI tract, aiding in the symptomatic relief of bloating and excessive gas. This combination would theoretically provide both antibiotic action against resistant infections (tebipenem) and symptomatic relief of dyspepsia/gas (antacids and simethicone). There is, however, no evidence that this four-drug combination is available as a single branded or generic product; the three-component antacid (aluminum hydroxide + magnesium hydroxide + simethicone) is available in products such as Mylanta, Maalox, and others[2][4][6][8]. Tebipenem pivoxil hydrobromide is marketed/developed separately as an antibiotic[1][3][5][7].

02

Targets

PBP (Penicillin-binding protein family)HCl (Hydrochloric acid)

Beyond the preview

Go deeper on tebipenem pivoxil hydrobromide + aluminum hydroxide + magnesium hydroxide + simethicone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tebipenem pivoxil hydrobromide + aluminum hydroxide + magnesium hydroxide + simethicone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call